Paving the Road to the Future of Chemoradiotherapy in Muscle-invasive Bladder Cancer: 10-year Follow-up of BC2001

Affiliations

¹ Department of Radiation Oncology, Stritch School of Medicine, Cardinal Bernardin Cancer Center, Loyola University Chicago, Maywood, IL, USA. Electronic address: asolanki@luc.edu.
² The James Buchanan Brady Urological Institute and Greenberg Bladder Cancer Institute, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
³ Department of Radiation Oncology, University of Maryland School of Medicine, Baltimore, MD, USA. Electronic address: phuoc.tran@som.umaryland.edu.

Editorial

Abhishek A Solanki et al. Eur Urol. 2022 Sep.

. 2022 Sep;82(3):280-282.

doi: 10.1016/j.eururo.2022.05.009. Epub 2022 May 28.

¹ Department of Radiation Oncology, Stritch School of Medicine, Cardinal Bernardin Cancer Center, Loyola University Chicago, Maywood, IL, USA. Electronic address: asolanki@luc.edu.
² The James Buchanan Brady Urological Institute and Greenberg Bladder Cancer Institute, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
³ Department of Radiation Oncology, University of Maryland School of Medicine, Baltimore, MD, USA. Electronic address: phuoc.tran@som.umaryland.edu.

No abstract available

Comment on

Chemoradiotherapy in Muscle-invasive Bladder Cancer: 10-yr Follow-up of the Phase 3 Randomised Controlled BC2001 Trial.
Hall E, Hussain SA, Porta N, Lewis R, Crundwell M, Jenkins P, Rawlings C, Tremlett J, Sreenivasan T, Wallace J, Syndikus I, Sheehan D, Lydon A, Huddart R, James N; BC2001 Investigators. Hall E, et al. Eur Urol. 2022 Sep;82(3):273-279. doi: 10.1016/j.eururo.2022.04.017. Epub 2022 May 14. Eur Urol. 2022. PMID: 35577644 Clinical Trial.